Leading Indian CRO to Improve Management of Endocrinology/Metabolic Disorder
RESEARCH TRIANGLE PARK, N.C., Sept. 30 /PRNewswire/ -- A global pharmaceutical company has initiated a prospective trial to evaluate the impact of insulin guidelines developed by the Indian National Consensus group in collaboration with Max Neeman, a leading India-based Contract Research Organization. The goal is to provide simple management to the Type II Diabetes patient dependent on insulin. The study will bring out a comparison between the routine clinical practice and the therapy decided as per the Insulin guidelines.
This large Phase IV study encompasses the northern, southern, western and eastern parts of India with over 1,200 sites and aims to enroll over 25,000 Type II Diabetics. Max Neeman is responsible for site management of all locations across the country and for achieving the enrollment target. To date, the team has successfully enrolled over 12,000 patients in 2 months time and will achieve the target before the stipulated time.
Max Neeman is experienced in endocrinology/metabolic studies having been awarded numerous diabetic trials to date with 98% patient retention rate and target enrollment met by the deadline.
About Max Neeman International
Max Neeman International is one of the leading CROs in India. Our specialty is that we offer services for the successful conduct of Phase I-IV clinical and device trials for small and mid-sized international and national Pharmaceutical, Biotechnology, Medical Device and Nutraceutical companies in compliance with ICH GCP standards. Operational since 2001, Max Neeman is an ISO 9001:2008 certified CRO for Monitoring, Site Management and Data Management Services. The company is presently active in over 31 cities with 6 regional offices. Contact Donald Swankie, Vice President of Business Development via email to [email protected] or call +1.919.424.3345. For more information please visit www.neeman-medical.com.
SOURCE Max Neeman International